At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 84 enrolled
Drug / intervention
secukinumab low dose +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-label, Multicenter Trial to Assess the Efficacy of Subcutaneous Secukinumab after12 Weeks of Treatment, and to Assess the Long-term Safety, Tolerability, Efficacy in Subjects From 6 to <18 Years of Age With Moderate to Severe Chronic Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating secukinumab low dose and secukinumab high dose for Moderate to Severe Chronic Plaque-type Psoriasis. Completed, enrolled 84 participants across 23 sites in 9 countries.
Detailed Summary
This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis. 84 subjects (most with moderate severity) were enrolled. Subjects were stratified by weight and disease severity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Czechia, Estonia, Germany, Peru, Poland, Russia, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartAug 2018
First PostedSep 2018
Primary CompletionSep 2019
Study CompletionSep 2023
TodayJul 2026
First PostedSep 12, 2018
Enrollment StartAug 29, 2018
Primary CompletionSep 19, 2019
Study CompletionSep 12, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.8 years ago
Interventions
secukinumab low dosedrug
dose depends on the weight group
secukinumab high dosedrug
dose depends on the weight group